Cameron Adams, PhD, October 24, 12-1 “Considerations for approval of the second live-attenuated, tetravalent dengue virus vaccine”
Abstract: The four dengue virus serotypes (DENV1-4) are a global health burden with 100 million symptomatic infections per year focused in the tropics. Primary DENV infection leads to lasting immunity against the infecting serotype but the resulting antibodies put individuals at risk for worse clinical outcomes when subsequently infected with a different serotype. This phenomenon … Read more